Untitled 3

Source R&D is the authoritative source of technology and services information supporting pharmaceutical and biotechnology companies in their drug discovery and development research projects.

Source R&D features extensive listings of service providers classified under company or organisation type, including contract chemical manufacturers; contract biologics manufacturers; biological research companies and organisations; and companies and organisations providing advisory, consultancy, legal, regulatory and other services.

The extensive coverage of Source R&D and the support of life sciences organisations One Nucleus and Bionow make it an invaluable reference tool that streamlines the vendor selection process to bring pharmaceutical/biotechnology companies and suppliers together.

Polyplus-transfection introduces new nanoparticle DNA transfection reagent

Polyplus transfection logo 7.12.18Polyplus-transfection SA, a developer of innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics, has introduced jetOPTIMUS, a new reagent for powerful nanoparticle DNA transfection.

“As cell and gene therapies become more advanced and complex, this increases the need to address DNA transfection of very challenging cells. To increase efficiency in hard-to-transfect cells, scientists have to use ever-more advanced reagents,” said Patrick Erbacher, the company’s CSO. “We recognised the need to combine the efficiency, safety and morphology requirements of mammalian cell transfection. To date, the market has not supplied what is expected today to fulfil all needs. Polyplus-transfection believes jetOPTIMUS will equip academics in the most advanced cell and gene therapy based research with the best solution.”

The reagent has been designed to be primarily used in academic research in the field of mammalian cells, especially hard-to-transfect cells. Polyplus-transfection says the reagent will result in the most efficient mammalian cell transfection product on the market, maximising gene expression, thus ensuring improved cell viability and morphology after transfection for more relevant data, and that the requirement of a minimal reagent volume and DNA quantity will considerably increase cost efficiency: the cost per reaction will be decreased by up to seven times when compared to other market leading products, the company claims.

For further information about Polyplus-transfection visit www.polyplus-transfection.com

Last modified onMonday, 10 December 2018 09:12